Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.29) by 13.79 percent. This is a 3200 percent decrease over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $11.571 million which missed the analyst consensus estimate of $13.413 million by 13.73 percent. This is a 91.19 percent increase over sales of $6.052 million the same period last year.